Atropine
Atropine is an anticholinergic medicine used across several injectable and ophthalmic products to treat poisoning, dangerously slow heart rate, and eye conditions including pupil dilation and lazy eye.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 50 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Atropine: Patient Information Guide
A plain-language walkthrough of Atropine — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Atropine is used across several products and routes for urgent medical situations, surgical preparation, and eye conditions. The specific approval depends on the product and route.
- Atropine Sulfate injection products are indicated for temporarily blocking life-threatening effects of an overactive nervous system — including treating symptomatic bradycardia (dangerously slow heart rate) and bradyasystolic cardiac arrest
- Atropine Sulfate injection is used as an antidote for poisoning by organophosphorus nerve agents, carbamate insecticides, or certain toxic mushrooms (muscarinic mushroom poisoning)
- ATROPEN Auto-Injector (intramuscular) is specifically indicated for organophosphorus nerve agent and insecticide poisoning in adults and pediatric patients
- Atropine Sulfate injection (Parenteral) is used before and during surgery to reduce saliva and airway secretions and to suppress unwanted vagal (nerve-related) reflexes during anesthesia
- Atropine Sulfate injection is used for gastrointestinal spasms, pylorospasm (stomach outlet spasm), and to relax the upper GI tract and colon during certain imaging procedures
- Atropine Sulfate injection is used for biliary and ureteral colic (spasm-related pain in the bile ducts or urinary tract), sometimes alongside morphine
- Atropine Sulfate injection has been used in parkinsonism, bronchial spasm, hypertonicity of the uterus, urinary bladder muscle disorders, and to control certain neurological symptoms from closed head injuries
- Atropine sulfate ophthalmic solution (including Isopto Atropine) is indicated for mydriasis (pupil dilation), cycloplegia (temporary paralysis of the focusing muscle), and penalization of the healthy eye in the treatment of amblyopia (lazy eye) in adults and children 3 months and older
- Atropine Sulfate eye ointment is indicated for mydriasis, cycloplegia, and pupil dilation in inflammatory conditions of the iris and uveal tract
⚙️How it works▾
Atropine blocks muscarinic receptors — the docking sites that acetylcholine (a key nerve messenger) normally binds to in the heart, gut, glands, lungs, and eyes. By occupying those receptors, atropine prevents acetylcholine from slowing the heart, stimulating secretions, causing muscle spasms, or over-stimulating organs. This is called competitive antagonism — meaning higher acetylcholine concentrations (such as from certain antidotes) can partially overcome atropine's block.
In the eye, blocking these receptors widens the pupil and locks the focusing muscle in a relaxed position. In poisoning from nerve agents or organophosphate insecticides — which flood the body with acetylcholine — atropine directly counteracts the dangerous over-stimulation of the nervous system.
💊How it's taken▾
How atropine is given depends entirely on the product and the condition being treated — there is no single schedule. Injection forms are administered by healthcare providers or, in the case of the ATROPEN Auto-Injector, by trained individuals in a poisoning emergency into the mid-outer thigh muscle. Eye drops and eye ointment are applied directly to the eye on a schedule set by an eye doctor.
- Injection dosing is individualized by the prescriber based on the specific use, the patient's weight, and their overall health
- The ATROPEN Auto-Injector is a single-dose emergency device — it is meant as a first response, not a complete treatment; seek medical care immediately after use
- Always follow your prescriber's instructions and the directions on your specific product label exactly
🤒Side effects — in detail▾
Common side effects of atropine reflect its action on the nervous system and include:
- Dry mouth and dry eyes
- Blurred vision and sensitivity to light (photophobia)
- Fast heartbeat (tachycardia) and palpitations
- Flushing and warm, dry skin
- Difficulty urinating or urinary retention
- Constipation, abdominal pain, or bloating
- Dizziness, headache, or confusion
- Nausea and vomiting
More serious reactions — including severe heart rhythm problems, acute glaucoma (sudden eye pain and vision change), hallucinations, seizures, high fever, or signs of a severe allergic reaction (throat swelling, trouble breathing) — require immediate medical attention.
⚠️Warnings & precautions▾
- Heart risks: Atropine can cause rapid or irregular heartbeat. In people with recent heart attack or severe coronary artery disease, it may worsen ischemia (reduced blood flow to the heart) or trigger dangerous arrhythmias. Use with caution in anyone with heart disease.
- Overheating: Atropine blocks sweating, which can lead to dangerous high body temperature — especially in children, during exercise, or in hot environments. Avoid excessive heat and physical activity after receiving atropine.
- Acute glaucoma: Atropine can trigger a sudden dangerous rise in eye pressure (acute angle-closure glaucoma) in susceptible individuals. Watch for eye pain or sudden vision changes.
- Urinary retention: People with bladder outflow obstruction may be unable to urinate after receiving atropine.
- Airway secretions: In people with chronic lung disease, atropine can thicken mucus and cause dangerous airway plugging. Respiratory status should be monitored closely.
- Pyloric stenosis: Atropine can turn a partial stomach outlet obstruction into a complete one — watch for GI symptoms.
- Allergic reactions: Serious allergic reactions including anaphylaxis have been reported.
🔀What it interacts with▾
Atropine has a small number of documented drug interactions to be aware of:
- Pralidoxime: When used together in poisoning treatment, signs of too much atropine (flushing, fast pulse, dry mouth, dilated pupils) can appear earlier and more intensely than expected, because pralidoxime boosts atropine's effects.
- Barbiturates: Atropine may increase the effects of barbiturate sedatives; barbiturates should be used with extra caution if needed for convulsions in this setting.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Tell your doctor if you have heart disease, coronary artery disease, or heart rhythm problems — atropine-induced rapid heart rate can be dangerous
- Tell your doctor if you have or are at risk for narrow-angle glaucoma — atropine can trigger a dangerous rise in eye pressure
- Tell your doctor if you have trouble urinating or a known bladder outflow obstruction
- Tell your doctor if you have pyloric stenosis or other stomach outlet problems
- Tell your doctor if you have chronic lung disease — atropine can worsen airway mucus
- If you have had a severe allergic reaction (anaphylaxis) to atropine before, tell your provider — medical supervision is required if atropine is still needed in a life-threatening emergency
- Pregnancy: Atropine crosses the placenta and reaches the fetus. Life-threatening emergencies should not go untreated — your provider will weigh the risks and benefits with you
- Breastfeeding: Small traces of atropine appear in breast milk. Consider pumping and discarding milk for 24 hours after receiving atropine before resuming breastfeeding
- Children under 2 years and adults over 65: Atropine stays in the body more than twice as long in these groups — effects may be stronger and last longer; careful dosing is important
🚑If you take too much▾
Too much atropine causes flushing, very dry skin and mouth, a racing heart, widely dilated pupils, high fever, blurred vision, and confusion. In severe cases, it can lead to hallucinations, delirium, seizures, coma, and life-threatening respiratory depression or circulatory collapse. Treatment is supportive — maintaining breathing, controlling fever (especially in children), managing seizures cautiously, and ensuring urinary output — and should be managed by medical professionals immediately.
📡Pharmacodynamics — effects in the body▾
Atropine's most important cardiovascular effect is speeding up a slow heart rate by releasing the brakes that the vagus nerve normally keeps on the heart. At low doses it may briefly slow the heart before this faster rate develops. It also widens the airways (bronchodilation), reduces saliva and other secretions, relaxes smooth muscle in the gut and urinary tract, and — in the eye — dilates the pupil and paralyzes the focusing muscle. Atropine can suppress sweating, which may raise body temperature, particularly in children or in hot conditions.
🔬Pharmacokinetics — how your body processes it▾
After intramuscular injection, atropine is absorbed quickly with peak blood levels reached around 30 minutes; exercise after injection significantly increases absorption. It distributes throughout the body and is about 44% bound to plasma proteins. Atropine is broken down mainly in the liver, with 13–50% eliminated unchanged in the urine, and has a blood half-life of about 2 to 4 hours in most adults. That half-life more than doubles in children under 2 years old and in adults over 65, meaning the drug lasts longer and effects are prolonged in these groups. Notably, organophosphate pesticides can slow atropine's own metabolism.
📦How to store it▾
Store between 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15ºC and 30ºC (between 59ºF and 86ºF) . Protect from light.
📄 Written from Atropine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Atropine — the kind of thing our pharmacy team would talk through with you at the counter.
Why am I being given atropine — what does it actually do? ▾
What side effects should I expect, and which ones mean I need to call for help? ▾
I'm using the ATROPEN auto-injector — how do I use it in an emergency? ▾
Is it safe to be in the heat or exercise after receiving atropine? ▾
I'm pregnant — is it safe for me to receive atropine? ▾
My child or elderly parent is receiving atropine — should I be extra watchful? ▾
Is Atropine available over the counter? ▾
When was Atropine first available? ▾
Who makes Atropine? ▾
💬 Answers drafted from Atropine’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Atropine comes
Atropine is available in 3 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- ATROPEN Auto-Injector is specifically indicated for treatment of poisoning by organophosphorus nerve agents or carbamate insecticides in adults and children
- Atropine Sulfate injection is used to treat symptomatic bradycardia (dangerously slow heart rate) and bradyasystolic cardiac arrest
- Atropine Sulfate injection is used as an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning
- Atropine Sulfate Parenteral injection is used before and during surgery to reduce saliva and airway secretions, and to suppress unwanted nerve-related effects during anesthesia
- ATROPEN Auto-Injector is given as a single intramuscular injection into the mid-outer thigh and is intended as initial emergency treatment — seek definitive medical care immediately after use
- Atropine Sulfate injection is typically given intravenously in medical settings, though intramuscular, subcutaneous, endotracheal, and intraosseous (into the bone) routes are also used depending on the situation
- Atropine Sulfate injection products should be inspected visually before use — do not use if the solution is not clear or the seal is not intact
- Dosing is individualized based on the condition being treated and the patient's weight and health — always follow the prescriber's instructions
Show 2 more strengths Show fewer strengths
Eye drops
How this form is used
- Atropine sulfate ophthalmic solution is used to dilate the pupil (mydriasis) and temporarily paralyze the eye's focusing muscle (cycloplegia) for eye exams
- Atropine sulfate ophthalmic solution is used to treat amblyopia (lazy eye) by penalizing the stronger eye
- Isopto Atropine 1% is indicated for mydriasis, cycloplegia, and penalization of the healthy eye in the treatment of amblyopia
- Indicated in adults and pediatric patients 3 months and older
- Atropine sulfate and Isopto Atropine eye drops are applied directly to the eye (ophthalmic route only)
- Follow your eye doctor's instructions on how many drops to use and how often
- These products are for use in the eye only — do not swallow or inject
Eye ointment
How this form is used
- Atropine Sulfate eye ointment is used to dilate the pupil (mydriasis) and paralyze the focusing muscle (cycloplegia) for eye exams
- Atropine Sulfate eye ointment is used when pupil dilation is needed in inflammatory conditions of the iris and uveal tract (the middle layer of the eye)
- Atropine Sulfate ointment is applied to the eye (ophthalmic route only)
- Follow your prescriber's instructions for how much to apply and how often
- For eye use only — do not swallow or inject
📊 Atropine across the U.S. market
How Atropine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (19) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
📈 How widely Atropine is used
A general measure of how commonly Atropine is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Atropine is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Atropine prescribed? Of the 1,596 medications we measure, Atropine ranks #494 by Medicaid prescriptions — more than 69% of them.
Utilization by Atropine product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
atropine sulfate 10 MG/ML Ophthalmic Solution Most dispensed
Summed across the 18 of 41 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1190655
1 ML atropine sulfate 0.4 MG/ML Injection
Summed across the 2 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1666781
10 ML atropine sulfate 0.1 MG/ML Prefilled Syringe
Summed across the 3 of 30 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1190546
atropine sulfate 0.4 MG/ML Injectable Solution
Summed across the 3 of 33 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1190776
1 ML atropine sulfate 1 MG/ML Injection
Summed across the 3 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1190795
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Atropine, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 29 of 138 listed Atropine NDCs with Medicaid activity.
🔍 Compare Atropine products
A representative set of FDA-listed product records for Atropine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Eye drops | ||||
| 10 mg/mL | Ophthalmic | A-S Medication Solutions × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | A-S Medication Solutions × 2 listings | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Akorn × 2 listings | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Akorn | NDA AUTHORIZED GENERIC | View NDC → |
| 10 mg/mL | Ophthalmic | Alcon Laboratories, Inc. × 3 listings | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Amneal Pharmaceuticals NY LLC × 9 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Apotex Corp. × 3 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Bausch & Lomb Americas Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 10 mg/mL | Ophthalmic | Bausch & Lomb Americas Inc. | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Bausch & Lomb Incorporated × 2 listings | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | Edenbridge Pharmaceuticals LLC. | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Gland Pharma Limited × 3 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Lifestar Pharma LLC × 6 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Mwi | NDA | View NDC → |
| 10 mg/mL | Ophthalmic | NorthStar RxLLC | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Redpharm Drug × 2 listings | ANDA | View NDC → |
| 10 mg/mL | Ophthalmic | Somerset Therapeutics, LLC × 4 listings | ANDA | View NDC → |
| 💊Eye ointment | ||||
| 10 mg/g | Ophthalmic | AvPAK | UNAPPROVED DRUG OTHER | View NDC → |
| 10 mg/g | Ophthalmic | Bausch & Lomb Incorporated × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 💊Injection | ||||
| 0.1 mg/mL | Intravenous | A-S Medication Solutions × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Parenteral | A-S Medication Solutions | UNAPPROVED DRUG OTHER | Find on DailyMed ↗ |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | A-S Medication Solutions | UNAPPROVED DRUG OTHER | Find on DailyMed ↗ |
| 0.05 mg/mL | Intravenous | Accord Healthcare, Inc., × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Accord Healthcare, Inc., × 3 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Accord Healthcare Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Accord Healthcare Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Intravenous | Accord Healthcare Inc. × 2 listings | NDA | View NDC → |
| 1 mg/mL | Intravenous | Accord Healthcare Inc. × 2 listings | NDA | View NDC → |
| 0.4 mg/mL | Intravenous | American Regent, Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | American Regent, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 1 mg/mL | Intravenous | American Regent, Inc. | ANDA | View NDC → |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | American Regent, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Intravenous | Amneal Pharmaceuticals LLC × 5 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Fresenius Kabi USA, LLC | NDA | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Fresenius Kabi USA, LLC | NDA | View NDC → |
| 0.1 mg/mL | Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc | UNAPPROVED DRUG OTHER | View NDC → |
| 0.05 mg/mL | Endotracheal; Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc. | NDA | View NDC → |
| 0.1 mg/mL | Intramuscular; Intravenous; Subcutaneous | General Injectables & Vaccines, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intravenous | Henry Schein, Inc | ANDA | View NDC → |
| 0.05 mg/mL | Endotracheal, Intramuscular, Intravenous, Subcutaneous | Henry Schein, Inc. | NDA | View NDC → |
| 0.05 mg/mL | Endotracheal; Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | Henry Schein, Inc. × 2 listings | ANDA | View NDC → |
| 0.1 mg/mL | Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. × 4 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Henry Schein, Inc. | NDA | View NDC → |
| 0.4 mg/mL | Intravenous | Henry Schein, Inc. | NDA | View NDC → |
| 1 mg/mL | Intravenous | Henry Schein, Inc. × 2 listings | NDA | View NDC → |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | Henry Schein, Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Intravenous | HF Acquisition Co., LLC, DBA Health First × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Intravenous | HF Acquisition Co. LLC, DBA Health First × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Parenteral | HF Acquisition Co LLC, DBA HealthFirst | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Endotracheal, Intramuscular, Intravenous, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | NDA | View NDC → |
| 0.1 mg/mL | Endotracheal; Intramuscular; Intravenous; Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | NDA | View NDC → |
| 0.4 mg/mL | Intramuscular, Intravenous, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | ANDA | View NDC → |
| 0.4 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 1 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst × 2 listings | ANDA | View NDC → |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | HF Acquisition Co LLC, DBA HealthFirst | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intravascular | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | Hikma Pharmaceuticals USA Inc. | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 1 mg/mL | Intravenous | Hikma Pharmaceuticals USA Inc. | ANDA | View NDC → |
| 0.05 mg/mL | Intravenous | Hospira, Inc. × 2 listings | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | Hospira, Inc. × 4 listings | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | International Medication Systems, Limited × 2 listings | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Medefil, Inc. × 2 listings | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Medical Purchasing Solutions, LLC × 3 listings | ANDA | View NDC → |
| 0.1 mg/mL | Parenteral | Medical Purchasing Solutions, LLC | UNAPPROVED DRUG OTHER | View NDC → |
| 0.1 mg/mL | Endotracheal, Intramuscular, Intravenous, Subcutaneous | Medical Purchasing Solutions, LLC | NDA | View NDC → |
| 0.4 mg/mL | Intramuscular, Intravenous, Subcutaneous | Medical Purchasing Solutions, LLC | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Medical Purchasing Solutions, LLC × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Intramuscular; Intravenous; Subcutaneous | Medical Purchasing Solutions, LLC × 3 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 0.4 mg/mL | Intravenous | Medical Purchasing Solutions, LLC × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Intravenous | Medical Purchasing Solutions, LLC × 2 listings | NDA | View NDC → |
| 0.4 mg/mL | Endotracheal; Intramedullary; Intramuscular; Intravenous; Subcutaneous | Medical Purchasing Solutions, LLC | ANDA | Find on DailyMed ↗ |
| 1 mg/mL | Intramuscular; Intravenous; Subcutaneous | Medical Purchasing Solutions, LLC × 2 listings | UNAPPROVED DRUG OTHER | View NDC → |
| 1 mg/mL | Intravenous | Medical Purchasing Solutions, LLC | NDA | View NDC → |
| 1 mg/mL | Intravenous | Medical Purchasing Solutions, LLC | ANDA | View NDC → |
| 0.25 mg/0.3 mL | Intramuscular | Meridian Medical Technologies LLC | NDA | View NDC → |
| 0.5 mg/0.7 mL | Intramuscular | Meridian Medical Technologies LLC | NDA | View NDC → |
| 1 mg/0.7 mL | Intramuscular | Meridian Medical Technologies LLC | NDA | View NDC → |
| 2 mg/0.7 mL | Intramuscular | Meridian Medical Technologies LLC × 2 listings | NDA | View NDC → |
| 0.1 mg/mL | Intravenous | ProPharma Distribution × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | ProPharma Distribution | NDA | View NDC → |
| 0.4 mg/mL | Intravenous | ProPharma Distribution | ANDA | View NDC → |
| 1 mg/mL | Intravenous | ProPharma Distribution | ANDA | View NDC → |
| 0.1 mg/mL | Intravenous | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Remedyrepack Inc. × 2 listings | ANDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Remedyrepack Inc. × 2 listings | NDA | View NDC → |
| 0.4 mg/mL | Endotracheal, Intramedullary, Intramuscular, Intravenous, Subcutaneous | Somerset Therapeutics, LLC | ANDA | View NDC → |
| 0.4 mg/mL | Intravenous | Somerset Therapeutics, LLC | ANDA | View NDC → |
| 1 mg/mL | Intravenous | Somerset Therapeutics, LLC | ANDA | View NDC → |
| 💊Bulk drug substance | ||||
| 1 kg/kg | — | Alchem International Private Ltd | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Amphastar Nanjing Pharmaceuticals, Inc. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Boehringer Ingelheim Pharma GmbH and Co. KG × 2 listings | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | C-squared Pharma Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | C-squared Pharma Sarl | BULK INGREDIENT | View NDC → |
| 1000 g/1000 g | — | Hubei Biocause Heilen Pharmaceutical Co., Ltd | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Kalchem International inc | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Laurus Labs Limited | BULK INGREDIENT | View NDC → |
| 1 g/g | — | Letco Medical, Llc | BULK INGREDIENT | View NDC → |
| 1 g/g | — | MEDISCA Inc.. | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Minsheng Group Shaoxing Pharmaceutical Co,. Ltd. × 2 listings | BULK INGREDIENT | View NDC → |
| 35 kg/35 kg | — | Nuray Chemicals Private Limited | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | Professional Compounding Centers of America dba PCCA | BULK INGREDIENT FOR HUMAN PRESCRIPTION COMPOUNDING | View NDC → |
| 1 kg/kg | — | Rolabo Outsourcing, S.L. × 2 listings | BULK INGREDIENT | View NDC → |
| 1 kg/kg | — | SCL Lifesciences Limited | BULK INGREDIENT | View NDC → |
| 4 kg/4 kg | — | Siegfried Grafton, Inc. | BULK INGREDIENT | View NDC → |
Showing 192 of 192 products — FDA National Drug Code Directory. See every product, package size and price: browse all 192 Atropine NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Atropine — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Atropine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Atropine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1223 7 dose forms · 28 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 1668013In current FDA listingsClinical drug / strength (SCD) 0.3 ML atropine sulfate 0.833 MG/MLRxCUI 11905360.7 ML atropine sulfate 0.714 MG/MLRxCUI 11905380.7 ML atropine sulfate 1.43 MG/MLRxCUI 11905400.7 ML atropine sulfate 2.86 MG/MLRxCUI 1190542 -
Dose form (SCDF) Injectable Solution RxCUI 370624In current FDA listingsClinical drug / strength (SCD) sulfate 0.3 MG/MLRxCUI 1190764sulfate 0.4 MG/MLRxCUI 1190776sulfate 0.54 MG/MLRxCUI 1145629sulfate 0.6 MG/MLRxCUI 1190787sulfate 1.25 MG/MLRxCUI 1190800 -
Dose form (SCDF) Injection RxCUI 1666780In current FDA listingsClinical drug / strength (SCD) 1 ML atropine sulfate 0.4 MG/MLRxCUI 16667811 ML atropine sulfate 1 MG/MLRxCUI 1190795 -
Dose form (SCDF) Ophthalmic Ointment RxCUI 374552In current FDA listings -
Dose form (SCDF) Ophthalmic Solution RxCUI 370964In current FDA listingsClinical drug / strength (SCD) sulfate 0.31 MG/MLRxCUI 1190766sulfate 0.62 MG/MLRxCUI 1190790sulfate 1 MG/MLRxCUI 1190796sulfate 1.25 MG/MLRxCUI 1190801sulfate 10 MG/MLRxCUI 1190655sulfate 2.5 MG/MLRxCUI 1190806sulfate 20 MG/MLRxCUI 1190817sulfate 5 MG/MLRxCUI 1190668 -
Dose form (SCDF) Oral Tablet RxCUI 370625No current FDA listingClinical drug / strength (SCD) sulfate 0.4 MGRxCUI 1190692sulfate 0.6 MGRxCUI 1190783 -
Dose form (SCDF) Prefilled Syringe RxCUI 727389No current FDA listingClinical drug / strength (SCD) 1 ML atropine sulfate 0.4 MG/MLRxCUI 12933115 ML atropine sulfate 0.05 MG/MLRxCUI 11905515 ML atropine sulfate 0.1 MG/MLRxCUI 11905525 ML atropine sulfate 0.4 MG/MLRxCUI 119055610 ML atropine sulfate 0.1 MG/MLRxCUI 1190546
Look up RxCUI 1223 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Atropine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
…and 16 more on the FDA NDC directory.
RxNorm drug class
Atropine belongs to the Anticholinergic class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 50 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Meridian Medical Technologies LLC is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.